Philip Ashton-Rickardt - Jan 3, 2022 Form 4 Insider Report for Sigilon Therapeutics, Inc. (SGTX)

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ Matthew Kowalsky, Attorney-in-Fact
Stock symbol
SGTX
Transactions as of
Jan 3, 2022
Transactions value $
$272,700
Form type
4
Date filed
1/4/2022, 03:15 PM
Previous filing
Jul 2, 2021
Next filing
Feb 22, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGTX Stock Option (Right to Buy) Award $273K +90K $3.03* 90K Jan 3, 2022 Common Stock 90K $3.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 30% on January 3, 2023 and 70% on January 3, 2024.